Saiqiao Biotech

Saiqiao Biotech (赛桥生物, also referred to as CytoBridge Bio or 赛桥方舟) is a Shenzhen-based biotech company founded in March 2020 that builds proprietary manufacturing equipment for cell and gene therapy (CGT). It positions itself as one of the top three globally—and the only domestic player—with fully independent intellectual property and supply chains for CGT new-quality productive forces, having moved from technology invention to scaled commercial application in roughly four years .

The company develops upstream key manufacturing technologies and core equipment to enable "one-click preparation and release" for cell and gene drugs, with a stated goal of pushing production costs below RMB 100,000 within five years and eventually making therapies accessible at the ten-thousand-yuan level . As of mid-2024, it had supported 33 leading pipelines across CAR-T, NK, TILs, TCR-T and gene therapy modalities, with clients reportedly filing for commercial marketing approval .

Saiqiao raised nearly RMB 200 million in a Series B round in June 2024 led by 3E Bioventures Capital (本草资本), with Hongsheng Capital (弘盛资本) joining and existing backers including Waterwood Capital (水木创投) and Shenzhen Angel Fund of Funds continuing to invest; Source Code Capital had led the Pre-B round . The company was founded and is led by CEO Shang Yuanfang (商院芳), a Tsinghua PhD whose work traces back to national bio-instrumentation major projects .